Prevention of Infections in the Neutropenic Patient

Clinical Infectious Diseases

Volumn 17, Issue , 1993, Pages S359-S367

  Verhoef, Jan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALOTIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FRAMYCETIN; GENTAMICIN; NEOMYCIN; NORFLOXACIN; NYSTATIN; QUINOLONE DERIVATIVE; ROXITHROMYCIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; VANCOMYCIN;

ACUTE LEUKEMIA; CONFERENCE PAPER; DISEASE ASSOCIATION; GRAM NEGATIVE INFECTION; HUMAN; INFECTION PREVENTION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ACUTE DISEASE; BACTERIAL INFECTIONS; COMMUNICABLE DISEASES; HUMAN; INFECTION CONTROL; LEUKEMIA; NEUTROPENIA; QUINOLONES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0027426859     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/17.Supplement_2.S359     Document Type: Article

References (54)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Bodey GP. Infections in cancer patients. Cancer Treat Rev 1975;2:89-128
3. Bodey GP, Rodriguez V, Chang H-Y, Narboni G. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978;41:1610-22.
4. Storring RA, Jameson B, McElwain TJ, Wiltshaw E. Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet 1977;2:837-40.
5. Weiser B, Lange M, Fialk M, Singer C, Szatrowski TH, Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial. Ann Intern Med 1981;95:436-8.
6. Nauseef WM, Maki DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981;304:448-53.
7. Dekker AW, Rozenberg-Arska M, Sixma JJ, Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med 1981;95:555-9.
8. The EORTC International Antimicrobial Therapy Project Group. Trimethoprim- sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 1984;150:372-9.
9. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebocontrolled trial. Ann Intern Med 1987;106:1-7.
10. Verhoef J, Rozenberg-Arska M, Dekker AW. Prevention of bacterial and fungal infections in granulocytopenic patients. Eur J Clin Oncol 1989;25:1345-50.
11. Schimpff SC. Infection prevention during profound granulocytopenia: new approaches to alimentary canal microbial suppression. Ann Intern Med 1980;93:358-61.
12. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
13. Cohen J, Donnelly JP, Worsley AM, Catovsky D, Goldman JM, Galton DAG. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet 1983;2:1452-4.
14. Schimpff SC. Surveillance cultures. J Infect Dis 1981;144:81-4.
15. LeFrock JL, Ellis CA, Weinstein L. The impact of hospitalization on the aerobic fecal microflora. Am J Med Sci 1979;227:269-74.
16. Remington JS, Schimpff SC. Please don’t eat the salads. N Engl J Med 1981;304:433-5.
17. Wells CL. Relationship between intestinal microecology and the translocation of intestinal bacteria. Antonie Van Leeuwenhoek 1990;58:87-93.
18. Schimpff SC. Infection prevention in patients with cancer and granulocytopenia. In: Grieco MH, ed. Infections in the abnormal host. New York: Yorke Medical Books, 1980:926-50.
19. Bodey GP. Current status of prophylaxis of infection with protected environments. In: Brown AE, Armstrong D, eds. Infectious complications of neoplastic disease: controversies in Management. New York: Yorke Medical Books 1985:381-94.
20. Bodey GP. Antimicrobial prophylaxis for infection in neutropenic patients. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Vol 9. New York: McGraw-Hill, 1988:1-43.
21. Cotton DJ, Pizzo PA. Prevention of infection in patients with hematologic malignancy. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds. Neoplastic diseases of the blood. Vol 2. New York: Churchill Livingstone 1985:919-41.
22. Bodey GP, Gehan EA, Freireich EJ, Frei E III. Protected environmentprophylactic antibiotic program in the chemotherapy of acute leukemia. Am J Med Sci 1971;262:138-51.
23. Levine AS, Siegel SE, Schreiber AD, et al. Protected environments and prophylactic antibiotics: a prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 1973;288:477-83.
24. Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia: laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-8.
25. Rodriguez V, Bodey GP, Freireich EJ, et al. Randomized trial of protected environment-prophylactic antibiotics in 145 adults with acute leukemia. Medicine (Baltimore) 1978;57:253-66.
26. Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 1973;32:1490-8.
27. Ribas-Mundo M, Granena A, Rozman C. Evaluation of a protective environment in the management of granulocytopenic patients: a comparative study. Cancer 1981;48:419-24.
28. European Organization for Research and Treatment of Cancer, Dietrich M, Gaus W, Vossen J, Van der Waaij D, Wendt F. Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. Infection 1977;5:107-14.
29. Armstrong D. Protected environments are discomforting and expensive and do not offer meaningful protection. In: Brown AE, Armstrong D, eds. Infectious complications of neoplastic diseases: controversies in management. New York: Yorke Medical Books, 1985:395-407.
30. Weber SF, Peacock JE, Do K-A, Cruz JM, Powell BL, Capizzi RL. Interaction of granulocytopenia and construction activity as risk factors for nosocomial invasive filamentous fungal disease in patients with hematologic disorders. Infect Control Hosp Epidemiol 1990;11:235-42.
31. Watson JG, Jameson B. Antibiotic prophylaxis for patients in protective isolation [letter]. Lancet 1979;1:1183.
32. Hahn DM, Schimpff SC, Fortner CL, Smyth AC, Young VM, Wiernik PH. Infection in acute leukemia patients receiving oral nonabsorbable antibiotics. Antimicrob Agents Chemother 1978;13:958-64.
33. King K. Prophylactic non-absorbable antibiotics in leukaemic patients. J Hyg (Camb) 1980;85:141-51.
34. Van der Waaij D, Berghuis-de Vries JM. Selective elimination of Enterobacteriaceae species from the digestive tract in mice and monkeys. J Hyg (Camb) 1974;72:205-11.
35. Van der Waaij D, Berghuis-de Vries JM. Determination of the colonization resistance of the digestive tract of individual mice. J Hyg (Camb) 1974;72:379-87.
36. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocvstis carinii pneumonitis. N Engl J Med 1977; 297:1419-26.
37. Enno A, Catovsky D, Darrell J, Goldman JM, Hows J, Galton DAG. Co-trimoxazole for prevention of infection in acute leukaemia. Lancet 1978;2:395-7.
38. Starke ID, Donnelly P, Catovsky D, Darrell J, Johnson SA, Goldman JM, Galton DAG. Co-trimoxazole alone for prevention of bacterial infection in patients with acute leukaemia. Lancet 1982;1:5-9.
39. Gurwith MJ, Brunton JL, Lank BA, Harding GKM, Ronald AR. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979;66:248-56.
40. Kauffman CA, Liepman MK, Bergman AG, Mioduszewski J. Trimethoprim- sulfamethoxazole prophylaxis in neutropenic patients: reduction of infections and effect on bacterial and fungal flora. Am J Med 1983;74:599-607.
41. Gualtieri RJ, Donowitz GR, Kaiser DL, Hess CE, Sande MA. Doubleblind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983;74:934-40.
42. Kramer BS, Carr DJ, Rand KH, et al. Prophylaxis of fever and infection in adult cancer patients: a placebo-controlled trial of oral trimethoprim- sulfamethoxazole plus erythromycin. Cancer 1984;53:329-35.
43. Henry SA, Armstrong D, Kempin S, Gee T, Arlin Z, Clarkson B. Oral trimethoprim/sulfamethoxazole in attempt to prevent infection after induction chemotherapy for acute leukemia. Am J Med 1984; 77:663-6.
44. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course ofamikacin for empirical therapy ofgram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8.
45. Wilson JM, Guiney DG. Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. N Engl J Med 1982;306:16-20.
46. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia: the trade-off for reduced gram-negative sepsis. Am J Med 1988;84:847-54.
47. Cruciani M, Concia E, Navarra A, et al. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children-perspective randomized study. Infection 1989;17:65-9.
48. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprimsulfamethoxazole and colistin. Ann Intern Med 1987;106:7-12.
49. Patoia L, Guerciolini R, Menichetti F, Bucaneve G, del Favero A. Norfloxacin and neutropenia [letter]. Ann Intern Med 1987;107:788-9.
50. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1990;88:36-42.
51. Rozenberg-Arska M, Dekker A, Verdonck L, Verhoef J. Prevention of bacteremia caused by a-hemolytic streptococci by roxithromycin (RU-28 965) in granulocytopenic patients receiving ciprofloxacin. Infection 1989;17:240-4.
52. Verhoef J, Rozenberg-Arska M, Dekker A. Prevention of infection in the neutropenic patient. Rev Infect Dis 1989;11(suppl 7):S1545-50.
53. Young LS. Antimicrobial prophylaxis in the neutropenic host: lessons of the past and perspectives for the future. Eur J Clin Microbiol Infect Dis 1988;7:93-7.
54. Fleer A, Timmerman CP, Besnier J, Pascual A, Verhoef J. Surface proteins of coagulase-negative staphylococci: their role in adherence to biomaterials and in opsonization. J Biomater Appl 1990;5: 154-65.